VK2735 is a novel dual agonist of the GLP-1 and GIP receptors, developed by Viking Therapeutics (NASDAQ: VKTX). Unlike single-target GLP-1 agonists such as semaglutide and tirzepatide, VK2735 simultaneously activates both the GLP-1 and GIP receptor pathways—the same dual mechanism as tirzepatide/Mounjaro, but with a distinct molecular structure and improved pharmacokinetic profile.
The compound features an extended half-life of 170–250 hours, enabling once-weekly subcutaneous dosing. Viking Therapeutics is also developing an oral formulation of VK2735, potentially offering patients an oral alternative to injectable GLP-1 therapies for weight management.
What is VK2735?
VK2735 is a novel dual agonist of the GLP-1 and GIP receptors, developed by Viking Therapeutics (NASDAQ: VKTX). Unlike single-target GLP-1 agonists such as semaglutide and tirzepatide, VK2735 simultaneously activates both the GLP-1 and GIP receptor pathways—the same dual mechanism as tirzepatide/Mounjaro, but with a distinct molecular structure and improved pharmacokinetic profile.
The compound features an extended half-life of 170–250 hours, enabling once-weekly subcutaneous dosing. Viking Therapeutics is also developing an oral formulation of VK2735, potentially offering patients an oral alternative to injectable GLP-1 therapies for weight management.
Phase 2 VENTURE Trial: Subcutaneous Efficacy
The VENTURE trial represents the first Phase 2 data for VK2735 in weight management. Published in Obesity in March 2026, the study evaluated weekly subcutaneous VK2735 in a randomized, double-blind, placebo-controlled design across 20 U.S. clinical sites.
Study Population and Design:
- •N = 176 adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities
- •13-week dose-ranging study
- •Primary endpoint: mean weight loss from baseline
Key Results:
- •Maximum mean weight loss: 14.7% at 13 weeks
- •Weight loss trajectory showed no plateau, suggesting ongoing efficacy beyond the study period
- •Safety profile comparable to placebo; majority of adverse events were mild to moderate
- •Treatment discontinuation rates were balanced between VK2735 and placebo arms
Citation: Bays HE, Toth P, Alkhouri N, et al. "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management." Obesity. 2026;34(3):537-549. DOI: 10.1002/oby.70106. PMID: 41508550.
This 14.7% weight loss at only 13 weeks is notable, particularly given the early stage of development and the observation that weight loss had not plateaued—suggesting potential for greater efficacy over longer treatment durations.
Oral Formulation: VENTURE-Oral Results (ECO 2026)
Recognizing the market demand for oral peptide therapeutics, Viking Therapeutics announced interim Phase 2 data for an oral VK2735 formulation at the European Congress on Obesity in Istanbul, April 2026.
Oral Dosing Results:
- •Once-daily oral VK2735 (formulation design not yet disclosed)
- •13-week treatment period
- •Mean weight loss: up to 12.2% (26.6 lbs) from baseline
- •Progressive weight loss observed from Week 1 onward
- •No weight-loss plateau during the study
While the oral formulation showed slightly lower efficacy than the subcutaneous weekly dosing (12.2% vs. 14.7%), this may reflect different dosing schedules and patient populations. The oral data represents a significant advancement for patients who prefer tablet administration over injections. Viking Therapeutics has announced plans for a Phase 3 oral program to follow.
Phase 3 VANQUISH Program: Current Status and Timeline
Viking Therapeutics launched two pivotal Phase 3 trials to support regulatory submission:
- •VANQUISH-1: ~4,500 patients enrolled in obesity indication; enrollment completed November 2025; 78-week treatment duration
- •VANQUISH-2: ~1,000 patients in Type 2 diabetes indication; enrollment completed Q1 2026; 78-week treatment duration
Both trials are designed to establish long-term safety and efficacy. The company has guided that Phase 3 results are expected in 2027, with an FDA approval timeline estimated for 2028–2029.
VK2735 vs. Tirzepatide: Same Targets, Different Molecules
Both VK2735 and tirzepatide activate GLP-1 and GIP receptors. This dual mechanism is what distinguishes them from first-generation GLP-1 agonists (semaglutide). However, they are distinct molecules with different molecular structures, pharmacokinetics, and regulatory status.
Efficacy Context:
- •Tirzepatide Phase 2: 21.4% weight loss over 72 weeks (SURMOUNT-1 data)
- •VK2735 Phase 2: 14.7% weight loss over 13 weeks
The early VK2735 data shows a comparable weight-loss trajectory, though direct comparative trials would be needed to establish equivalence or superiority.
Safety and Tolerability
The VENTURE trial reported that the majority of adverse events were mild to moderate in severity. The most commonly reported adverse events in GLP-1/GIP dual agonist trials generally include gastrointestinal effects (nausea, vomiting, diarrhea), which typically decrease over time as patients develop tolerance.
Research Outlook and FDA Timeline
VK2735 represents an important entry in the competitive GLP-1 agonist landscape. If Phase 3 trials meet primary endpoints and safety is established, Viking Therapeutics could file for FDA approval by late 2027 or early 2028. The dual agonist mechanism, combined with oral and subcutaneous options, positions VK2735 as a meaningful competitor to tirzepatide.
Key regulatory milestones to watch:
- •Phase 3 results in 2027
- •FDA submission 2028
- •Potential approval 2028–2029
Frequently Asked Questions
How does VK2735 work?
VK2735 is a dual agonist, meaning it activates both the GLP-1 and GIP receptors. These receptors regulate appetite, glucose metabolism, and weight. By stimulating both pathways, VK2735 enhances weight loss and glycemic control.
What is the difference between VK2735 and tirzepatide?
Both are GLP-1/GIP dual agonists, but they are distinct molecules. Tirzepatide (Mounjaro/Zepbound) is FDA-approved; VK2735 remains in clinical trials. VK2735 features an extended half-life and is being developed in both subcutaneous and oral forms.
When will VK2735 be approved by the FDA?
Based on current trial timelines, FDA approval is estimated for 2028–2029, assuming successful Phase 3 results. Phase 3 data are expected in 2027.
Is VK2735 currently available for purchase?
No. VK2735 is an investigational compound available only in clinical trials. It is not approved by the FDA or any regulatory authority for use outside research settings. Tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) are currently the only FDA-approved GLP-1 agonists on the market.
Research Use Only Disclaimer
VK2735 is not approved for human use and is available only within clinical trials or for research purposes. This article is provided for educational and informational purposes only and does not constitute medical advice. VK2735 has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. Do not use VK2735 outside of authorized clinical trials or as directed by a licensed healthcare provider participating in an approved clinical study.
This article was last updated September 2026 based on the most recent publicly available clinical trial data and company announcements.